U.S. Physical Therapy, Inc. USPH R2KR3KPHARMA
Company Overview
U.S. Physical Therapy, Inc., together with its subsidiaries, operates and manages outpatient physical therapy clinics. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. U.S. Physical Therapy, Inc. was founded in 1990 and is based in Houston, Texas.
Why Investors Should Care
Offers a dividend yield of 2.41%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $780.99M (+16.3% YoY); net profit $39.58M.
- Trailing 12 Months Year-on-year growth — revenue +8.5%, earnings -56.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.8%, profit CAGR 7.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.84% |
| 1 Year: | 8.50% |
Compounded Profit Growth
| 5 Years: | 7.88% |
| 1 Year: | -56.50% |
Stock Price Performance
| 1 Year: | -8.69% |
| 6 Months: | -0.90% |
| 3 Months: | +24.98% |
| 1 Month: | +3.72% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross6d ago
- RSI (14)55.41 · Neutral
P/E of 157.66 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 157.7.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | USPH U.S. Physical Therapy, Inc. R2KR3KPHARMA | 78.83 | 157.66 | $1.20B | 2.41% | 8.14% | 6.51% | 8.84% | 7.88% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 97.56M | 104.25M | 103.03M | 109.20M | 108.34M | 115.10M | 113.12M | 117.35M | 116.23M | 126.37M | 117.25M | 122.11M | 112.72M | 83.86M | 108.93M | 112.37M | 126.93M | 125.89M | 131.70M | 140.66M | 139.60M | 148.51M | 151.49M | 150.01M | 155.68M | 167.19M | 168.03M | 183.79M | 197.34M | 197.13M | 198.29M | 214.06M |
| Gross Profit | 16.84M | 21.14M | 18.87M | - | 20.50M | 23.06M | 19.66M | - | 20.75M | 24.53M | 21.19M | - | 23.21M | 27.15M | 26.08M | 25.22M | 26.72M | 31.43M | 27.37M | 26.96M | 15.69M | 19.28M | 30.36M | 25.90M | 34.30M | 29.80M | 26.59M | 30.82M | 26.78M | 30.86M | 32.21M | 27.93M | 28.40M | 33.86M | 29.13M | 31.07M | 41.62M | 36.87M | 32.75M | 41.94M |
| Operating Income | 9.19M | 13.55M | 11.95M | 12.61M | 11.49M | 15.03M | 12.05M | 10.95M | 12.20M | 15.68M | 12.89M | 13.96M | 13.05M | 17.03M | 15.43M | 14.80M | 15.43M | 19.90M | 16.82M | 15.29M | 4.01M | 10.26M | 19.93M | 15.02M | 22.23M | 16.93M | 15.03M | 20.08M | 14.89M | 17.00M | 20.06M | 15.88M | 14.93M | 15.57M | 12.85M | 19.64M | 24.94M | 25.33M | 12.48M | 21.95M |
| Net Income | 4.01M | 6.33M | 5.51M | - | 4.49M | 6.01M | 4.80M | - | 4.82M | 4.94M | 5.15M | - | 7.12M | 9.25M | 8.10M | - | 8.44M | 14.62M | 9.05M | - | 1.02M | 10.23M | 10.92M | 8.17M | 12.44M | 10.01M | 8.80M | 11.20M | 9.56M | 7.41M | 10.92M | 9.25M | 8.05M | 7.51M | 6.63M | 9.90M | 12.39M | 13.14M | 5.04M | 9.90M |
| Diluted EPS | 0.34 | 0.48 | 0.47 | 0.48 | 0.43 | 0.57 | 0.46 | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.20 | 0.99 | 0.61 | 0.21 | 0.82 | 0.66 | 0.67 | 0.87 | 0.72 | 0.58 | 0.64 | 0.51 | 0.46 | 0.47 | 0.39 | 0.80 | 0.58 | 0.48 | -0.12 | 0.25 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 201.41M | 211.23M | 231.52M | 249.65M | 264.06M | 305.07M | 331.30M | 356.55M | 414.05M | 453.91M | 481.97M | 422.97M | 495.02M | 553.14M | 604.80M | 671.35M | 780.99M |
| Gross Profit | - | 56.01M | 55.87M | 62.91M | 64.70M | 76.17M | 78.36M | 82.01M | 90.62M | 101.66M | 112.47M | 94.45M | 117.18M | 112.02M | 121.51M | 123.92M | 149.69M |
| Operating Income | 28.25M | 33.19M | 31.43M | 38.41M | 38.77M | 45.77M | 47.29M | 49.53M | 54.73M | 60.31M | 67.42M | 52.41M | 70.65M | 56.80M | 50.51M | 62.99M | 86.68M |
| Net Income | 11.77M | 15.64M | 20.97M | 17.93M | 12.72M | 19.13M | 20.61M | 20.55M | 22.26M | 34.87M | 40.04M | 35.19M | 40.83M | 32.16M | 28.24M | 31.42M | 39.58M |
| Diluted EPS | 1.00 | 1.32 | 1.75 | 1.51 | 1.05 | 1.62 | 1.77 | - | - | - | 2.45 | 2.48 | 2.41 | 2.25 | 1.28 | 1.84 | 1.42 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 140.86M | 163.25M | 171.71M | 224.13M | 244.55M | 281.25M | 292.15M | 299.97M | 303.76M | 335.74M | 338.00M | 334.54M | 351.23M | 418.98M | 443.17M | 630.50M | 594.36M | 749.43M | 858.15M | 997.24M | 1.17B | 1.20B |
| Total Equity | 87.82M | 92.22M | 103.96M | 107.05M | 117.32M | 128.29M | 146.28M | 156.11M | 161.33M | 166.84M | 171.06M | 174.73M | 180.29M | 184.24M | 187.55M | 204.87M | 215.94M | 240.26M | 276.16M | 295.61M | 315.79M | 476.19M | 488.93M | 476.43M |
| Cash & Equivalents | - | - | 9.18M | 9.98M | 11.67M | 12.90M | 14.27M | 14.56M | 12.97M | 20.56M | 15.78M | 19.21M | 20.45M | 15.02M | 20.05M | 21.93M | 23.37M | 23.55M | 32.92M | 28.57M | 31.59M | 152.82M | 41.36M | 35.57M |
| Long Term Debt | - | - | - | 23.78M | 17.57M | 40.65M | 34.73M | - | - | - | 48.34M | - | - | - | 50.60M | 56.73M | 38.40M | 50.36M | 16.60M | 117.59M | 175.83M | 138.99M | 142.53M | 152.59M |
| Total Liabilities | - | - | 24.48M | 41.67M | 37.05M | 69.01M | 69.96M | 123.44M | 128.92M | 131.60M | 131.45M | 159.50M | 156.32M | 149.17M | 162.54M | 110.34M | 92.35M | 181.39M | 184.39M | 296.98M | 373.59M | 345.00M | 408.42M | 433.81M |
| Current Liabilities | - | - | 14.23M | 16.32M | 16.31M | 23.17M | 25.50M | 21.40M | 21.70M | 21.36M | 19.01M | 24.18M | 28.98M | 26.38M | 24.62M | 39.55M | 41.95M | 60.56M | 93.49M | 83.48M | 85.49M | 102.19M | 116.28M | 139.04M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 30.94M | 30.52M | 32.66M | 39.25M | 44.80M | 45.19M | 37.52M | 51.05M | 56.53M | 73.00M | 62.45M | 100.00M | 76.41M | 58.54M | 81.98M | 74.94M | 75.06M |
| Investing Cash Flow | -7.33M | -21.63M | -31.61M | -14.10M | -52.45M | -22.88M | -26.12M | -32.49M | -43.58M | -23.91M | -37.99M | -51.20M | -124.14M | -81.27M | -45.02M | -149.45M | -36.71M |
| Financing Cash Flow | -27.30M | -6.14M | -245.00K | -23.46M | 8.88M | -20.94M | -9.89M | -14.29M | -11.06M | -47.66M | -24.27M | -39.42M | 43.38M | 25.76M | 84.27M | -36.95M | -44.14M |
| Share Buybacks | 5.59M | 1.40M | 4.66M | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 5.57M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | 26.5% | 24.1% | 25.2% | 24.5% | 25.0% | 23.7% | 23.0% | 21.9% | 22.4% | 23.3% | 22.3% | 23.7% | 20.3% | 20.1% | 18.5% | 19.2% |
| Operating Margin % | 14.0% | 15.7% | 13.6% | 15.4% | 14.7% | 15.0% | 14.3% | 13.9% | 13.2% | 13.3% | 14.0% | 12.4% | 14.3% | 10.3% | 8.4% | 9.4% | 11.1% |
| Net Margin % | 5.8% | 7.4% | 9.1% | 7.2% | 4.8% | 6.3% | 6.2% | 5.8% | 5.4% | 7.7% | 8.3% | 8.3% | 8.2% | 5.8% | 4.7% | 4.7% | 5.1% |
| ROE % | 12.8% | 15.0% | 19.6% | 15.3% | 9.9% | 13.1% | 12.1% | 11.0% | 10.9% | 16.1% | 16.7% | 12.7% | 13.8% | 10.2% | 5.9% | 6.4% | 8.3% |
| ROCE % | - | 26.2% | 21.4% | 24.7% | 19.3% | 20.9% | 16.6% | 15.2% | 14.4% | 15.0% | 11.8% | 10.5% | 10.6% | 7.4% | 5.6% | 6.0% | 8.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.17% | 2.26M | $178.03M |
| 2 | Bahl & Gaynor LLC | 5.77% | 861.57K | $67.75M |
| 3 | Kayne Anderson Rudnick Investment Management LLC | 5.67% | 846.67K | $66.57M |
| 4 | Copeland Capital Management, LLC | 5.64% | 841.54K | $66.17M |
| 5 | State Street Corporation | 4.74% | 707.19K | $55.61M |
| 6 | Morgan Stanley | 4.68% | 698.69K | $54.94M |
| 7 | Vanguard Capital Management LLC | 4.52% | 674.20K | $53.01M |
| 8 | Neuberger Berman Group, LLC | 4.01% | 598.89K | $47.09M |
| 9 | American Century Companies Inc | 3.74% | 558.82K | $43.94M |
| 10 | SouthernSun Asset Management, LLC | 3.54% | 527.76K | $41.50M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for USPH
Avoiding Lag: Real-Time Signals in (USPH) Movement - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPMjdORUNZcjZPMmxBMnVUMEd3ei03dEVKWWVlQUxVU3NsZ2huQURjRjJpUFdaS2dOcVBHNGd5WEZNMy1PNm5WcmZrTVc1Z3ZpTVBPRlExdlRoS0NDaW1WTkx3cXUxc1NyWVpxdHBvN21YR3EzSWN6Vk5GT01KaUg0OFdoS0lKdjVGdE1Nd0…
3 Reasons USPH is Risky and 1 Stock to Buy Instead - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOM241ZC12MVY5cWt2MkhFVnBwVVpYdmFNTmR0MXB5UWJtWTlkdHVaeTM1QzZUVTJqeU9zaHZKMDRJYy00ZzdNUFlJNGQwcG53RlpTbWlmVTZhOEVOYVp1SmJpNmh5OEQwSjlGYjNobFo4U245OHVPWXVqbzQ4N3BSVk84azdWMXg3RGdFcF…
U.S. Physical Therapy (USPH) Stock Is Up, What You Need To Know - StockStory
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNUG9ZWDdfS3RnVFFnUXBSZU8wcXJjOVhEdUxTMWNzeEx1ZkFzRk9lNFlnWnpwQ3VxSzZOX2tEREJsSjlTTkV1X1UyLVlVUDJYbHd1bWJoNEU2VEpEb3ZOYmZ6WkJCOTA3b2dMa2FEWGFlT2ZZbU5KY0VrbnhSNVRJRWxSRTZzT3RrbWpDa1…
Is 24.7% Fall In US Physical Therapy (USPH) Stock A Buying Opportunity? - Trefis
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNS1RfVnFzMkNzejllbmJqNy1Wc0RhUndhSjhnQ0tQSWZTek10MFpUVTBtSzZ4UmI0ZXdJWGdaMXh0c1ROYVJlV1pKbFV5aFVOWEdmX2lUZFlOVjJfd2VsbkRRYlNnZGFzZ3NGSFpYeTBaUjRaSDA5eVRoZlhCOWRKODJhYTVUem9XSUJtaE…
798 outpatient locations across 45 states: U.S. Physical Therapy presents at a Midwest conference - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQUDlDM1VySVlmWTg2Z1lwTEl5UGVOdWxidW9xdl9HTE1Sa1BsZ1gwcmYyeEZWOWRYSDNUcm9GUHp5NTlOQXprN3QzSkp2cnREa3dsWmJMMGpFcEVzT0dkSlpTaGJyZkhrZk1QYmxGVEFHRGpXeUhFdnlQZGd1YlNxWEZuNzRsVE53dTdmUk…
Outpatient & Specialty Care Stocks Q2 Teardown: U.S. Physical Therapy (NYSE:USPH) Vs The Rest - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxOMmJqenNmY2xGUHVXNUMzT0J1bFQ1T3BXQmtHWmR3b3c2R2FZWTMxUEhTemJreGNoSE1BQ1Q5R0VZaC1yd1BNVk8ydkhWTW1DRGYxR3ltR0FhMlhxUEZQTFdiRHF5SjJuWENEY0F3bFVsczRZb0FTRURucG5JRk42M3Rmd3hqcWpCLVV4SU…
USPH — Frequently Asked Questions
What is the current share price of U.S. Physical Therapy, Inc. (USPH)?
As of 2026-09-07 16:24 PDT, U.S. Physical Therapy, Inc. (USPH) trades at $78.83 on NYSE. Its 52-week range is $58.22 to $90.82.
What is the market capitalisation of USPH?
U.S. Physical Therapy, Inc. (USPH) has a market capitalisation of $1.20B on NYSE.
What is the P/E ratio of USPH?
USPH trades at a trailing price-to-earnings (P/E) ratio of 157.66. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.60.
Does USPH pay a dividend?
U.S. Physical Therapy, Inc. (USPH) currently offers a dividend yield of 2.41%.
What is the return on equity (ROE) of USPH?
USPH has a return on equity (ROE) of 6.51%. Its return on capital employed (ROCE) is 8.14%.
Is USPH a good stock to buy?
This page provides a data-driven analysis of U.S. Physical Therapy, Inc. (USPH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.